The FDA in early October cleared an MR scanner for use in neurosurgery. The PoleStar N-10, Odin Medical Technologies' 0.12-tesla permanent magnet system, rises from under the operating table to sandwich the patient's head and provide real-time
The FDA in early October cleared an MR scanner for use in neurosurgery. The PoleStar N-10, Odin Medical Technologies' 0.12-tesla permanent magnet system, rises from under the operating table to sandwich the patient's head and provide real-time guidance.
"This is not a diagnostic imaging tool, but it is sufficient to provide the neurosurgeon with the key answer, and that is whether to continue to cut or not," said Hillel Bachrach, president of Odin, the Israeli firm that developed the system.
The intraoperative scanner, which lists for $960,000, can be installed in a standard operating room suite outfitted with the proper radio-frequency shielding and equipped with MR-compatible tools, Bachrach said. Preparing the site for MR operations bumps the cost higher, with the final tally dependent on the particulars of the individual site. Shielding is minimized, however, by a compact magnetic field with a 5-gauss line that extends just 5 feet from the magnet's isocenter.
The final cost may be a bargain, considering the end result: access to real-time data indicating whether the tumor has been completely removed. Competing real-time systems, the Hitachi Airis II and GE Signa SP/i open mid-field systems, cost $900,000 to $2 million, respectively. Less costly alternatives, such as neuronavigational tools that process MR data obtained prior to surgery, cannot account for the shifting of brain tissue that occurs during an operation.
The gap between the two magnets in the PolerStar is wide enough to fit the patient's head in any position, while providing sufficient access for the surgeon. Real-time images guide the procedure, allowing continuous evaluation of a tumor resection prior to closure of the surgical wound.
Obtaining real-time data with Odin's PoleStar N-10 promises to yield anatomical precision. Among the possible patient benefits from more accurate surgery are quicker recuperation time, shorter hospital stays, fewer complications, and less potential for recurrence, according to the company.
Odin was founded in September 1995. R&D is concentrated in Yokneam, Israel, and the company opened a subsidiary this year to support sales and marketing operations in the U.S. Four units have been installed at sites around the world: one each in Zurich and Israel, and two in the U.S., at the Cleveland Clinic and the University of Medicine and Dentistry of New Jersey. By year's end, three additional sites are scheduled to open in the U.S., Bachrach said.
The PoleStar was officially unveiled at the American Association of Neurological Surgeons convention in April and was most recently exhibited at the Congress of Neurological Surgeons in September. It will not, however, be on display at the upcoming RSNA meeting, as company executives have chosen to focus sales efforts entirely on neurosurgeons.
"It is not an imager; it is a navigation systema neurosurgery tool," Bachrach said. "So there is no need for a radiologist to be involved."
Bachrach plans to sell the system in the U.S. using its own sales force as well as sales agents under the direction of Odin.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.